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AbstrACt
Introduction Cow’s milk is a dietary staple for children 
in North America. Though clinical guidelines suggest 
children transition from whole (3.25% fat) milk to 
reduced (1% or 2%) fat milk at age 2 years, recent 
epidemiological evidence supports a link between 
whole milk consumption and lower adiposity in children. 
The purpose of this trial is to determine which milk 
fat recommendation minimises excess adiposity and 
optimises child nutrition and growth.
Methods and analysis Cow’s Milk Fat Obesity 
pRevention Trial will be a pragmatic, superiority, parallel 
group randomised controlled trial involving children 
receiving routine healthcare aged 2 to 4–5 years who 
are participating in the TARGet Kids! practice- based 
research network in Toronto, Canada. Children (n=534) 
will be randomised to receive one of two interventions: 
(1) a recommendation to consume whole milk or (2) a 
recommendation to consume reduced (1%) fat milk. 
The primary outcome is adiposity measured by body 
mass index z- score and waist circumference z- score; 
secondary outcomes will be cognitive development 
(using the Ages and Stages Questionnaire), vitamin D 
stores, cardiometabolic health (glucose, high- sensitivity 
C- reactive protein, non- high density lipoprotein (non- 
HDL), low density lipoprotein (LDL), triglyceride, HDL 
and total cholesterol, insulin and diastolic and systolic 
blood pressure), sugary beverage and total energy 
intake (measured by 24 hours dietary recall) and cost 
effectiveness. Outcomes will be measured 24 months 
postrandomisation and compared using analysis of 
covariance (ANCOVA), adjusting for baseline measures.
Ethics and dissemination Ethics approval has been 
obtained from Unity Health Toronto and The Hospital for 
Sick Children. Results will be presented locally, nationally 
and internationally and published in a peer- reviewed 
journal. The findings may be helpful to nutrition guidelines 
for children in effort to reduce childhood obesity using 
a simple, inexpensive and scalable cow’s milk fat 
intervention.
trial registration number NCT03914807; pre- results.
bACkground
Inexpensive and widely accessible cow’s milk 
has been a dietary staple for children in North 
America for over a century. The majority of 
North American children consume cow’s 
milk on a daily basis.1 2 Cow’s milk provides 
children with nutrients for growth and devel-
opment such as protein, carbohydrates, 
calcium, vitamins A and D and fat. The 
National Health Service,3 Canadian Paedi-
atric Society4 and the American Academy of 
Pediatrics5 recommend whole (3.25% fat) 
cow’s milk for children beginning at 1 year 
of age to support optimal development in a 
strengths and limitations of this study
 ► Cow’s Milk Fat Obesity pRevention Trial (CoMFORT) 
addresses a common and clinically important prob-
lem through the evaluation of two nutritional inter-
ventions in primary healthcare.
 ► Nesting CoMFORT within the TARGet Kids! prospec-
tive cohort study may improve follow- up and allow 
future study of intervention effects later in childhood.
 ► Using a patient- centred proportional consent model 
may enhance inclusion of under- represented groups 
and increase study efficiency.
 ► While the pragmatic intervention is a physician rec-
ommendation, adherence to the recommended milk 
fat content may be variable.
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period of rapid growth and high energy demand.6 7 In 
an effort to curb childhood obesity, children are recom-
mended to transition from whole to reduced fat (1% 
or 2%) cow’s milk starting at 2 years of age.3–5 However, 
this recommendation is based on low quality evidence 
(Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE)8 score of 0–1)9 derived 
primarily from consensus opinion.9 10
It is unclear whether switching from whole milk to 
reduced fat milk at age 2 years is beneficial. Observational 
evidence supports that children who consume whole milk 
have a lower risk of overweight or obesity relative to chil-
dren who consume reduced (0.1%–2%) fat milk.11–13 
A systematic review and meta- analysis of observational 
evidence for the relationship between cow’s milk fat and 
child adiposity reported that children who consumed 
whole milk had 1/3 lower odds of overweight and obesity 
compared with children who consumed reduced (0.1%–
2%) fat milk.14 Proposed mechanisms include higher 
satiety offered by whole milk due to hormonal responses 
to dietary milk fat consumption13 15 thus displacing 
nutrient- poor foods or sugary beverages. Another theory 
is that a low fat, high protein diet in early childhood 
may programme a ‘thrifty metabolism’, where the body 
adapts by storing excess energy as fat.16 Conversely, a 
higher fat diet may metabolically programme higher 
energy utilisation and lower energy storage.16 17 Fatty 
acids found in cow’s milk, such as trans- palmitoleic acid 
and conjugated linoleic acid, may be protective against 
excess adiposity.18 19 Reverse causality could also explain 
this relationship, where parents may choose milk with 
a fat content to counter- balance the adiposity of their 
child (ie, higher fat milk for a leaner child).20 Given the 
financial burden of overweight and obesity on healthcare 
systems worldwide,21 determining which milk fat recom-
mendation in childhood is effective in lowering a child’s 
risk of developing excess adiposity, may result in substan-
tial healthcare savings in the future.
It is possible that cow’s milk fat may also result in other 
beneficial health effects. Higher circulating levels of trans- 
palmitoleic acid have been associated with lower adiposity, 
low density lipoprotein (LDL) cholesterol, insulin resis-
tance and triglycerides, and positively associated with high 
density lipoprotein (HDL) cholesterol, in several large 
adult cohort studies.18 During early childhood, dietary 
fat consumption is known to support cognitive develop-
ment, which usually concludes around 6 years of age.22 
Cow’s milk fat may promote brain development due to its 
essential fatty acid content (eg, linoleic acid) which may 
manifest in gains across multiple developmental domains 
including social, emotional and physical.23 24 The ratio 
of essential fatty acids linoleic to alpha- linoleic acid (n-6 
to n-3) in whole cow’s milk is believed to optimise circu-
lating docosahexaeonic acid,25 which is an important fatty 
acid to brain growth and function.26
Parents and clinicians have expressed interest in 
evidence- based guidelines for milk fat during early child-
hood, but rely on different nutrition information sources 
including primary healthcare recommendations.27 Both 
whole and reduced fat milk are currently recommended 
to families with young children receiving primary health-
care.27 To inform clinical practice and evidence- based 
guidelines, randomised controlled trial evidence is 
needed to determine whether switching to reduced fat 
milk at 2 years of age or continuing with whole milk 
beyond 2 years of age results in improved growth, cardio-
vascular and cognitive developmental outcomes.
objECtIvEs
overall objective
To determine whether a primary healthcare recommen-
dation for whole (3.25% fat) versus reduced fat (1% 
fat) milk in early childhood can: (1) reduce adiposity; 
(2) improve cardiovascular health; (3) improve cogni-
tive development; (4) increase vitamin D stores and (5) 
reduce sugary beverage consumption and total energy 
intake at 24 months postrandomisation.
Hypotheses
We hypothesise that recommending whole milk between 
1 and 4–5 years of age versus transitioning to reduced fat 
milk at 2 years will result in the following outcomes at 24 
months postrandomisation:
 ► Primary outcome: lower excess adiposity measured by: 
(1) body mass index z- score (zBMI) and (b) waist 
circumference z- score (zWC).
 ► Secondary outcome 1: lower risk of cardiovascular disease 
measured by: blood pressure, non- HDL, LDL, triglyc-
eride, HDL and total cholesterol, glucose, insulin, 
high- sensitivity C- reactive protein (hsCRP) and glyco-
sylated haemoglobin.
 ► Secondary outcome 2: higher vitamin D status measured 
by serum 25- hydroxyvitamin D (25(OH)D).
 ► Secondary outcome 3: better cognitive developmental 
scores measured by the Ages and Stages Question-
naire (ASQ) and the Early Development Instrument 
(EDI).
 ► Secondary outcome 4: lower sugary beverage consump-
tion and total energy intake measured by the Auto-
mated Self- Administered 24 hours Recall tool 
(ASA-24).
 ► Secondary outcome 5: lower financial costs to both fami-
lies and the healthcare system.
study dEsIgn And MEtHods
This will be a pragmatic, parallel group, superiority, 
randomised controlled trial. The study will include two 
active arms: (1) primary healthcare recommendation to 
consume whole milk starting at 2 years of age and (2) 
primary healthcare recommendation to consume reduced 
fat (1%) milk starting at 2 years of age. This protocol has 
been designed following the 2013 Standard Protocol 
Items: Recommendations for Interventional Trials guide-
lines28 and registered at  clinicaltrials. gov. Trial results will 
3Vanderhout SM, et al. BMJ Open 2020;10:e035241. doi:10.1136/bmjopen-2019-035241
Open access
Figure 1 Trial flow diagram. CoMFORT, Cow’s Milk Fat 
Obesity pRevention Trial.
be reported according to the Consolidated Standards of 
Reporting Trials guidelines for pragmatic trials.29
study setting
Healthy children aged 1.5–2.99 years will be recruited 
during a routine well- child doctor’s visit at 12 partici-
pating TARGet Kids! academic paediatric or family medi-
cine group practices in Toronto and Montreal over 2 
years. The TARGet Kids! primary care research network 
and children’s longitudinal cohort study is a collabora-
tion between academic health outcome researchers at the 
University of Toronto, McGill University and a network of 
over 100 university affiliated primary healthcare providers 
( www. targetkids. ca).30 Children participating in TARGet 
Kids! provide anthropometric, lifestyle and develop-
mental information and a blood sample at routine well- 
child visits. Recruitment started in February 2020 and is 
expected to take 24 months to complete enrolment.
Inclusion criteria
Children who are: (1) healthy by parental report (charac-
terised as not living with chronic or acute illness, except 
for asthma); (2) 1.5–2.99 years of age; (3) involved in a 
TARGet Kids! academic paediatric or family medicine 
group; (4) are from families with verbal communication 
in English or French.
Exclusion criteria
Children who: (1) have Prader- Willi syndrome or other 
syndrome associated with obesity; (2) have severe devel-
opmental delay which impacts daily functioning; (3) are 
considered failure to thrive (children with zBMI values 
≤−2 are unlikely to benefit from obesity prevention); (4) 
are siblings of trial participants as families may share milk 
or (5) do not consume cow’s milk by choice, lactose intol-
erance or allergy.
Interventions
During a scheduled well- child visit, children aged 1.5–2.99 
years will be randomised to one of two interventions 
currently provided in primary care27: (1) whole fat milk 
recommendation and (2) reduced fat milk recommen-
dation (figure 1). Standardised training sessions based 
on current clinical guidelines will be provided to partic-
ipating primary care providers with quarterly reminders 
to ensure consistency in the provided recommendations. 
For children randomised to either group, research assis-
tants will notify the child’s physician of their allocated 
recommendation immediately prior to the clinical 
encounter. All participating healthcare providers have 
provided consent to participate in the randomisation 
process. Intervention scripts for physicians can be found 
in the online supplementary file.
Whole milk recommendation
Children randomised to the whole milk recommendation 
will receive a primary care recommendation to consume 
500 mL of whole fat (3.25%) milk per day instead of 
transitioning to reduced fat (1%) milk at 2 years of age. 
Parents will also be provided bi- monthly email reminders. 
Children who receive the whole milk recommendation 
will be provided with the same age- appropriate nutri-
tional recommendations for foods other than cow’s milk 
as children who receive the reduced fat recommendation 
as part of routine healthcare according to the Rourke 
Baby Record.31
Reduced fat milk recommendation
Children randomised to the reduced fat group will receive 
a primary care recommendation to transition from whole 
milk to 500 mL of reduced fat (1%) milk per day once the 
child is 2 years of age (consistent with current guidelines). 
Parents will also be provided bi- monthly email reminders. 
Children who receive the reduced fat recommendation 
will be provided with the same age- appropriate nutri-
tional recommendations for foods other than cow’s milk 
as children who receive the whole fat recommendation as 
part of routine healthcare according to the Rourke Baby 
Record.31
Adherence
Multiple methods will be used to maximise adherence to 
milk recommendations: (1) primary healthcare providers 
will be reminded to repeat milk recommendations at up 
to two subsequent well- child visits during study participa-
tion; (2) research assistants will provide participants with 
reminder magnets specific to their allocation group (see 
online supplementary file) after receiving milk fat recom-
mendations from the physician and (3) participants will 
receive an email survey bi- monthly which will ask about 
the enrolled child’s recent milk consumption and remind 
families of the milk fat recommendation provided to 
them (see online supplementary file 1 for email script).
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baseline participant characteristics
The following baseline variables will be measured: age, 
sex, zBMI, z- height, birth weight, waist circumference, 
ethnicity, maternal age and education level, duration of 
breast feeding, current and past vitamin D supplemen-
tation, daily volume of cow’s milk intake, daily multivi-
tamin use, parental BMI, screen viewing time, physical 
activity, sleep time and total dietary intake in the past 24 
hours using the standardised TARGet Kids! data collec-
tion instrument adapted from the Canadian Community 
Health Survey32: cognitive development will be measured 
using the ASQ.33
Follow-up outcome measures
Follow- up of parents and children will occur at 24 months 
postrandomisation, which has been used in previous 
childhood obesity prevention trials.34 35 Follow- up will be 
completed by trained research assistants at each practice 
site during routine healthcare using the same techniques 
as baseline.
Primary outcome
The primary outcome will adiposity, measured by 
the mean difference in age- standardised and sex- 
standardised zBMI which will be measured at 24 months 
postrandomisation. zBMI is an important outcome that 
is predictive of adiposity in later childhood, adolescence 
and adulthood.36 37 Using standardised anthropometric 
protocols,38 39 trained research assistants will measure 
children’s height using a Healthometer Stadiometer 
(Healthometer, Boca Raton, Florida, USA) and weight 
will be measured using a digital Healthometer Scale 
(Healthometer). BMI will be calculated as weight (kg) 
divided by height (m2). zWC will also be used to assess 
adiposity, and will be measured by trained research assis-
tance according to standardised anthropometric proto-
cols.38 39 Waist circumference has been associated with 
future weight gain, diabetes and cardiovascular disease 
and is the recommended measure for children with 
obesity.40–43 Both BMI and WC will be standardised using 
the WHO growth references ranges (zBMI and zWC)44 45 
which reflect optimal childhood growth and are recom-
mended for clinical use in Canada.46 Velocity of zBMI 
change (from baseline to trial termination), which is 
predictive of higher BMI in adolescence and adulthood, 
will be used to measure differences in growth rate.37 47
Secondary outcomes
Cardiovascular health
Laboratory measures including glucose, hsCRP, non- 
HDL, LDL, triglyceride, HDL and total cholesterol, 
insulin and diastolic and systolic blood pressure will be 
obtained since these measures track from childhood to 
adulthood and are important early indicators of cardio-
vascular health.48–51 Non- fasting blood samples will be 
taken during the clinic visit by TARGet Kids! research 
assistants who are trained phlebotomists. Non- fasting 
measures have been established as equivalent to fasting 
measures, which are not feasible from young children.52 
Existing paediatric reference standards will be used to 
identify high risk children or the 90th percentile when 
these are unavailable.53
Vitamin D
Vitamin D will be measured by serum 25(OH)D concen-
tration from venous blood at baseline and follow- up using 
isotope dilution liquid chromatography tandem mass 
spectrometry54 by the Mount Sinai Services (MSS) Labo-
ratory ( mountsinaiservices. ca).55
Child cognitive development
Child cognitive development will be assessed by parental 
report using the ASQ33 at enrolment and follow- up 
visits. The ASQ is a parent completed developmental 
questionnaire which has been cross- culturally vali-
dated and is routinely used during primary healthcare 
as recommended by the American Academy of Pediat-
rics. It identifies children at risk of developmental delay 
across five domains: communication, gross motor, fine 
motor, problem solving and personal social behaviour. 
In addition, the junior and senior kindergarten teacher 
completed EDI will be collected in both junior and senior 
kindergarten to assess overall child development and 
school readiness. The EDI is collected across Canada 
for population- level monitoring of child development 
and covers five developmental domains: physical health 
and well- being, social competence, emotional maturity, 
language and cognitive development, communication 
skills and general knowledge.56–58
Sugary beverage and total energy intake
The Automated Self- Administered 24 hours Assessment 
(ASA24) from the National Cancer Institute of the 
National Institutes of Health will be used to measure 
sugary beverage and total energy intake at baseline and 
follow- up.59 Differences in fat intake from both cow’s 
milk and other dietary sources of fat will be evaluated. 
The ASA24 is a web- based tool that allows 24 hours food 
recall modelled after the United States Department of 
Agriculture (USDA) Automated Multiple- Pass Method. 
The ASA24 has been validated for sugary beverage and 
total energy intake and has been piloted in Ontario chil-
dren aged 2–5 years for feasibility of completion within 
30 min.59–61
sample size
Previous obesity prevention trials have established a clin-
ically meaningful zBMI difference of ≥0.25.62 63 To detect 
this difference, 426 children will be required in each 
group (n=213 per group), based on an alpha of 0.05 with 
80% power. To accommodate 20% loss to follow- up,64 534 
1.5–2.99 years old children will be recruited (n=267 per 
group) over 2 years and subsequently followed for 2 years.
recruitment
Recruitment strategies include recruitment in person by a 
trained research assistant who is known to them through 
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the TARGet Kids! programme at a routine primary health-
care visit and collecting non- invasive measures (question-
naires and anthropometric measures) while the child and 
family wait for their primary healthcare provider visit.
randomisation
Children will be randomised using a 1:1 allocation ratio 
to either group. Randomisation will be computer gener-
ated with variable block sizes, and will be stratified by site 
to ensure a balanced distribution of participants between 
groups within each of the sites.65 Web- based central rando-
misation will be used to preserve allocation concealment. 
After a child has been determined eligible to participate 
in CoMFORT and parents provide informed consent, 
research assistants will access the online central randomis-
ation system to ascertain the child’s randomisation status.
blinding
Due to the nature of the study, children and parents 
cannot be blind, but they will be blind to the trial 
hypotheses. Primary healthcare providers who provide 
the recommendations also cannot be blind. Allocation 
concealment will be preserved for research assistants and 
parents who may enrol participants depending on rando-
misation sequence if they are aware of it.
retention and complete collection of data
Every reasonable attempt (including phone calls and 
emails) will be made to locate CoMFORT subjects at 
follow- up. All families will be reminded via phone call to 
attend their scheduled annual well- child visit, consistent 
with routine practice. To further reduce loss to follow- up, 
parents who have moved out of district will be offered to 
visit The Hospital for Sick Children for repeat laboratory, 
cognitive and anthropometric testing.
data management
The Applied Health Research Centre of the Li Ka Shing 
Knowledge Institute of St. Michael’s Hospital and Peter 
Gilgan Centre for Research and Learning of The Hospital 
for Sick Children will be the data coordinating centres. 
Study data were collected and managed using Research 
Electronic Data Capture (REDCap) electronic data 
capture tools hosted at St. Michael’s Hospital.66 REDCap 
is a secure, web- based application designed to support 
data capture for research studies, providing: (1) an intu-
itive interface for validated data entry; (2) audit trails for 
tracking data manipulation and export procedures; (3) 
automated export procedures for seamless data down-
loads to common statistical packages and (4) procedures 
for importing data from external sources. Laboratory 
tests from the MSS Laboratory will be directly uploaded 
through a secure web portal.
statistical analysis
Descriptive statistics for baseline characteristics (frequen-
cies and proportions for discrete variables; means and 
SDs for symmetric variables; medians and IQRs for 
skewed data) will be used to evaluate randomisation 
completeness. The intent- to- treat principle will be 
applied to the analysis of outcomes.67 68 Although rando-
misation is expected to balance the covariates, variables 
that demonstrate, by chance, a potentially clinically 
meaningful imbalance, will be considered as adjusting 
covariates. For the primary analysis, zBMI at 24 months 
postrandomisation will be compared between groups 
using ANCOVA adjusting for baseline zBMI. Because 
zBMI is age standardised, minimal differences in age at 
follow- up will be accounted for. For the secondary anal-
yses, group differences in cognitive developmental scores, 
serum 25(OH)D concentration, cardiometabolic factors, 
sugary beverage and total energy intake will be compared 
using linear regression. Piecewise linear mixed models 
will be used to determine differences in growth rates 
between groups.
Cost effectiveness
An economic analysis will be conducted to determine the 
incremental costs (or cost- savings) of whole versus reduced 
fat cow’s milk in reducing childhood adiposity, from both 
health system and societal perspectives. The time horizon 
will be limited to 5 years to leverage patient level data 
and minimise uncertainty from modelling a longer time 
horizon. All costs, parameter estimates and ranges will 
be derived from study data and will be obtained using 
medical record extraction. Publicly available Ontario 
costing sources will be used to cost resource utilisation 
parameters. Cost- effectiveness will be expressed as the 
incremental cost- effectiveness ratio (ICER), calculated by 
dividing the incremental costs between the intervention 
arms by the incremental change in child’s zBMI between 
baseline and the end of the follow- up period. Costs will 
be adjusted for inflation using the Canadian Consumer 
Price Index and reported in 2022 Canadian dollars. An 
extensive one- way deterministic sensitivity analysis will be 
performed to evaluate the robustness of the results and 
evaluate uncertainty in any of the assumptions. Ranges 
for the sensitivity analysis will be obtained from 95% CIs 
generated from study data for each of the parameters. 
Probabilistic sensitivity analysis using Monte Carlo simu-
lation will be used to further evaluate uncertainty and 
establish a point estimate and 95% CI around the ICER. 
Economic evaluation analyses will be carried out through 
the Ontario Child Health SPOR SUPPORT Unit.
Ethics and dissemination
Approval has been obtained for the CoMFORT trial from 
the Unity Health Toronto (REB# 18-369) and Hospital 
for Sick Children (REB# 1000063023) Research Ethics 
Boards. Findings will be disseminated directly to primary 
healthcare providers and to parents. A meeting of all the 
TARGet Kids! practices, research team and policy leaders 
(representatives from the University of Toronto Section 
of Community Paediatrics, Family and Community Medi-
cine, Ontario Medical Association, Maternal, Infant, 
Child and Youth Research Network, College of Family 
Physicians, Canadian Paediatric Society and parent 
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representatives) and public health agencies (Public 
Health Ontario and Public Health Agency of Canada) 
will occur annually. Downstream dissemination to 
primary healthcare providers will occur through formal 
and informal avenues at local levels, such as City Wide 
Paediatric Rounds, national Continuing Medical Educa-
tion events and those held by local physician groups. 
Both parent and clinician members of the parent panel 
will play an integral role in communicating trial evidence 
by participating in the development of all dissemination 
material. End of grant knowledge will be shared with the 
academic community through multiple publications in a 
high impact journal as well as presentations at national 
and international conferences.
Consent
A stepwise proportionate consent model will be used for 
this study.69 First, during the TARGet Kids! cohort study 
consent process, participants consent to be approached 
for additional research. As the second step, partici-
pants who consent to TARGet Kids! and are eligible 
for CoMFORT will be approached to participate in 
CoMFORT by research assistants at either the 18- month 
or 2- year well- child visit. Proportionate consent will be 
sought according to the National Health Service (UK) 
proportionate consent guidelines,69 which have four 
components: providing a (1) verbal description of the 
study, (2) information sheet to participants (3) answering 
participant questions and (4) documenting informed 
consent.69 TARGet Kids! research assistants will verbally 
provide information to each eligible family about the 
nature and purpose of the research, in addition to the 
material risks, benefits and alternatives, and provide an 
information sheet about the CoMFORT trial. Informed, 
written consent will then be obtained before randomisa-
tion. A copy of the CoMFORT consent form can be found 
in the online supplementary file.
Patient and public involvement
Parents and clinicians identified this research question 
as important and relevant in a qualitative study using 
interviews and online questionnaires.27 A TARGet Kids! 
parent panel informed all aspects of this protocol to 
maximally meet the needs of parents and children, 
including revising patient- facing materials about the 
intervention and consent forms and guiding the design 
of the recruitment process. Parents verified the inter-
vention as designed was appropriate and feasible. Over 
the course of this trial, the parent panel will meet 
virtually as needed and in person at least once every 
6 months to discuss recruitment, study promotion and 
overall progress. Parents’ experiences will be valued as 
evidence and an integral part of the research process. 
Parent partners will contribute to knowledge transla-
tion strategies, coauthor study publications and attend 
conferences alongside investigators to present study 
findings.
IMPACt
Results from this trial will be applicable to practice and 
nutrition guidelines because: (1) two widely accepted, 
clinically relevant alternatives will be directly compared; 
(2) a diverse sample of healthy children participating in 
routine healthcare will be involved; (3) practice settings 
representing the range of primary healthcare practice 
will be included (family medicine, primary care paedi-
atrics, community health centres, etc); (4) patient- 
important health outcomes will be measured including 
adiposity, child cognitive development and nutrition 
and (5) the multidisciplinary team includes clinicians, 
parents and policymakers as partners in the research 
process. The CoMFORT trial has been created through 
meaningful collaboration with parents through gover-
nance, conducting research and knowledge translation. 
In doing so, the results of the CoMFORT trial will be well 
positioned for implementation and integration into the 
lives of children and families.
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